This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Onyx Therapeutics, Inc.. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: The Innovative Contributions of Jeremiah Degenhardt
Introduction
Jeremiah Degenhardt is a notable inventor based in San Mateo, CA. He has made significant contributions to the field of biotechnology, particularly in cancer treatment methodologies. His work focuses on the use of biomarkers to enhance treatment regimens for tumors.
Latest Patents
Degenhardt holds a patent titled "Immunoglobulin expression levels as biomarker for proteasome inhibitor response." This patent outlines methods for treating tumors in subjects and determining effective treatment regimens. The methods involve measuring the expression levels of immunoglobulin, FCGR2B, or a combination thereof. The patent also includes related kits, computer-readable storage media, and systems that utilize processors for implementation.
Career Highlights
Jeremiah Degenhardt is currently associated with Onyx Therapeutics, Inc., where he continues to advance his research and innovations. His work has the potential to significantly impact the way tumors are treated, providing new avenues for patient care.
Collaborations
Degenhardt collaborates with talented professionals in his field, including Brian Tuch and Andrea Loehr. These partnerships enhance the research and development efforts at Onyx Therapeutics, Inc.
Conclusion
Jeremiah Degenhardt's innovative work in the field of biotechnology exemplifies the importance of research in developing effective cancer treatments. His contributions through patents and collaborations continue to pave the way for advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile